FI104260B1 - Biologisesti aktiivista yhdistelmä-DNA-ihmisentekij-VIII-johdannaista koodittava DNA, tämän sisältävä yhdistelmä-DNA-ilmentämisvektori ja isäntäsolu sekä menetelmä biologisesti aktiivisen yhdistelmä-DNA-ihmisentekijä-VIII-johdannaisen valmistamiseksi - Google Patents

Biologisesti aktiivista yhdistelmä-DNA-ihmisentekij-VIII-johdannaista koodittava DNA, tämän sisältävä yhdistelmä-DNA-ilmentämisvektori ja isäntäsolu sekä menetelmä biologisesti aktiivisen yhdistelmä-DNA-ihmisentekijä-VIII-johdannaisen valmistamiseksi

Info

Publication number
FI104260B1
FI104260B1 FI922745A FI922745A FI104260B1 FI 104260 B1 FI104260 B1 FI 104260B1 FI 922745 A FI922745 A FI 922745A FI 922745 A FI922745 A FI 922745A FI 104260 B1 FI104260 B1 FI 104260B1
Authority
FI
Finland
Prior art keywords
factor viii
human factor
biologically active
recombinant human
dna
Prior art date
Application number
FI922745A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI104260B (fi
FI922745A0 (fi
Inventor
Annelie B Almstedt
Eva Maria Gray
Kerstin Larsson
Peter Lind
Helena Inga Sandberg
Jack Spira
Mona Sydow-Baeckman
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20377785&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI104260(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Publication of FI922745A0 publication Critical patent/FI922745A0/fi
Application granted granted Critical
Publication of FI104260B publication Critical patent/FI104260B/fi
Publication of FI104260B1 publication Critical patent/FI104260B1/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Oxide Ceramics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Confectionery (AREA)
FI922745A 1989-12-15 1992-06-12 Biologisesti aktiivista yhdistelmä-DNA-ihmisentekij-VIII-johdannaista koodittava DNA, tämän sisältävä yhdistelmä-DNA-ilmentämisvektori ja isäntäsolu sekä menetelmä biologisesti aktiivisen yhdistelmä-DNA-ihmisentekijä-VIII-johdannaisen valmistamiseksi FI104260B1 (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE8904239 1989-12-15
SE8904239A SE465222C5 (sv) 1989-12-15 1989-12-15 Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
PCT/SE1990/000809 WO1991009122A1 (fr) 1989-12-15 1990-12-06 Derive du facteur humain viii de recombinaison
SE9000809 1990-12-06

Publications (3)

Publication Number Publication Date
FI922745A0 FI922745A0 (fi) 1992-06-12
FI104260B FI104260B (fi) 1999-12-15
FI104260B1 true FI104260B1 (fi) 1999-12-15

Family

ID=20377785

Family Applications (1)

Application Number Title Priority Date Filing Date
FI922745A FI104260B1 (fi) 1989-12-15 1992-06-12 Biologisesti aktiivista yhdistelmä-DNA-ihmisentekij-VIII-johdannaista koodittava DNA, tämän sisältävä yhdistelmä-DNA-ilmentämisvektori ja isäntäsolu sekä menetelmä biologisesti aktiivisen yhdistelmä-DNA-ihmisentekijä-VIII-johdannaisen valmistamiseksi

Country Status (21)

Country Link
EP (3) EP1293513A3 (fr)
JP (1) JP2644084B2 (fr)
AT (2) ATE232213T1 (fr)
AU (1) AU645539B2 (fr)
BR (1) BR9007921A (fr)
CA (1) CA2071875C (fr)
DE (3) DE19975066I2 (fr)
DK (2) DK0786474T3 (fr)
ES (2) ES2189897T3 (fr)
FI (1) FI104260B1 (fr)
HK (2) HK1009290A1 (fr)
HU (1) HU211504A9 (fr)
IE (1) IE904510A1 (fr)
LU (1) LU90457I2 (fr)
NL (1) NL990035I2 (fr)
NO (1) NO309041B1 (fr)
NZ (1) NZ236276A (fr)
PT (1) PT96208B (fr)
SE (1) SE465222C5 (fr)
SG (1) SG66753A1 (fr)
WO (1) WO1991009122A1 (fr)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6060447A (en) * 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
IL86693A (en) 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins that have the activity IIIV of the blood, a process for their preparation that uses cells are produced through genetic engineering and pharmaceutical preparations that contain them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
SE468050C (sv) * 1991-03-15 1998-04-27 Pharmacia & Upjohn Ab Rekombinant derivat av human faktor VIII
US5663060A (en) * 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5744446A (en) * 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5364771A (en) * 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5888974A (en) * 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
DK53792D0 (da) * 1992-04-24 1992-04-24 Novo Nordisk As Fremgangsmaade til fremstilling af proteiner
WO1994007510A1 (fr) * 1992-10-02 1994-04-14 Kabi Pharmacia Ab Composition comprenant une formulation d'un facteur de coagulation viii, procede pour sa preparation et utilisation d'un agent tensioactif comme stabilisateur
SE9300509D0 (sv) * 1993-02-16 1993-02-16 Kabi Pharmacia Ab Peg treatment
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
SE9303601D0 (sv) * 1993-11-01 1993-11-01 Kabi Pharmacia Ab Improved cell cultivation method and medium
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
SE503424C2 (sv) * 1994-11-14 1996-06-10 Pharmacia Ab Process för rening av rekombinant koagulationsfaktor VIII
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
AU6455896A (en) * 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
EP1318198B1 (fr) * 1996-05-14 2006-03-22 Biovitrum Ab Procédé pour produire un polypeptide recombine comprenant l'addition d'un inhibiteur de chymotrypsines au milieu de culture cellulaire
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
JP2002517180A (ja) * 1997-12-05 2002-06-18 ジ・イミユーン・リスポンス・コーポレーシヨン 増大された発現を示す新規ベクターおよび遺伝子
US7820796B2 (en) 1998-03-12 2010-10-26 Genetics Institute, Llc. Methods for producing Factor VIII proteins
US6797505B2 (en) * 1998-05-27 2004-09-28 Cell Genesys, Inc. Recombinant AAV vectors for gene therapy of hemophilia A
US6200560B1 (en) * 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
JP5149470B2 (ja) 1999-02-22 2013-02-20 バクスター・インターナショナル・インコーポレイテッド 新規のアルブミンを含有していない第ｖｉｉｉ因子処方物
SE9901379D0 (sv) 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
MXPA02009221A (es) * 2000-03-22 2005-07-25 Octagene Gmbh Produccion de factores de coagulacion sanguineo recombinantes en lineas celular humanas.
AU2004236174B2 (en) 2001-10-10 2011-06-02 Novo Nordisk A/S Glycopegylation methods and proteins/peptides produced by the methods
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
EP1520008B1 (fr) 2002-07-09 2012-09-05 Baxter International Inc. Milieu exempt de proteines animales pour la culture de cellules
LT1596887T (lt) 2003-02-26 2022-04-25 Nektar Therapeutics Polimero-faktoriaus viii fragmento konjugatai
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
ES2648241T3 (es) 2003-09-30 2017-12-29 The Trustees Of The University Of Pennsylvania Clados de virus adenoasociados (AAV), secuencias, vectores que contienen el mismo, y usos de los mismos
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
DK2586456T3 (en) 2004-10-29 2016-03-21 Ratiopharm Gmbh Conversion and glycopegylation of fibroblast growth factor (FGF)
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
MX350293B (es) 2004-11-12 2017-09-04 Bayer Healthcare Llc Modificacion dirigida al sitio del factor viii.
EP1858543B1 (fr) 2005-01-10 2013-11-27 BioGeneriX AG Facteur de stimulation de colonie de granulocytes glycopegylé
EP1707634A1 (fr) 2005-03-29 2006-10-04 Octapharma AG Procédé pour l'isolation de protéines recombinantes
US8999678B2 (en) 2005-04-07 2015-04-07 The Trustees Of The University Of Pennsylvania Method of increasing the function of an AAV vector
EP2386571B1 (fr) 2005-04-08 2016-06-01 ratiopharm GmbH Compositions et méthodes utilisées pour la préparation de mutants par glycosylation de l'hormone de croissance humaine résistant à la protéase
EP1739179A1 (fr) 2005-06-30 2007-01-03 Octapharma AG Transfection stable exempt de sérum et production des protéines recombinantes humaines dans des lignées cellulaires humaines
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
PL3121266T3 (pl) 2006-01-04 2020-07-13 Baxalta Incorporated Wolne od oligopeptydów pożywki do hodowli komórkowej
US7982010B2 (en) 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US7985839B2 (en) 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
KR20080108147A (ko) 2006-03-31 2008-12-11 백스터 인터내셔널 인코포레이티드 페질화된 인자 ｖｉｉｉ
EP2049144B8 (fr) 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylation de peptides par l'intermédiaire de séquences de glycosylation à liaison o
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
ES2521490T3 (es) 2006-12-15 2014-11-12 Baxter International Inc. Conjugado de factor VIIa - ácido (poli)siálico con una vida media in vivo prolongada.
CN101646779B (zh) 2007-02-23 2014-12-03 Sk化学株式会社 制备和纯化因子viii及其衍生物的方法
CN101796063B (zh) 2007-04-03 2017-03-22 拉蒂奥法姆有限责任公司 使用糖聚乙二醇化g‑csf的治疗方法
ES2551123T3 (es) 2007-06-12 2015-11-16 Ratiopharm Gmbh Proceso mejorado para la producción de azúcares de nucleótido
US9359629B2 (en) 2007-12-27 2016-06-07 Baxalta Incorporated Cell culture processes
MX2010009154A (es) 2008-02-27 2010-09-09 Novo Nordisk As Moleculas conjugadas del factor viii.
LT2393828T (lt) 2009-02-03 2017-01-25 Amunix Operating Inc. Prailginti rekombinantiniai polipeptidai ir juos apimančios kompozicijos
ES2966234T3 (es) 2009-06-09 2024-04-18 Prolong Pharmaceuticals Llc Composiciones de hemoglobina
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
KR101832937B1 (ko) 2009-07-27 2018-02-28 박스알타 인코퍼레이티드 혈액 응고 단백질 복합체
SG10201401194VA (en) 2009-07-27 2014-07-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
ES2590679T3 (es) 2009-07-27 2016-11-23 Lipoxen Technologies Limited Glicopolisialilación de proteínas diferentes a proteínas de coagulación de la sangre
EP2470559B1 (fr) 2009-08-24 2017-03-22 Amunix Operating Inc. Compositions de facteur ix de coagulation et leurs procédés de fabrication et d'utilisation
GB0915481D0 (en) 2009-09-04 2009-10-07 Arecor Ltd Stable manufacture of factor V111
MX336830B (es) 2009-12-06 2016-02-03 Biogen Hemophilia Inc Polipeptidos hibridos y quimericos del factor viii-fc, y metodos de uso de los mismos.
WO2011095604A1 (fr) 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Prolongation de la demi-vie de protéines
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
CA2793633A1 (fr) 2010-03-29 2011-10-13 The Trustees Of The University Of Pennsylvania Systeme d'ablation de transgene induit pharmacologiquement
WO2012006635A1 (fr) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Molécules à chaîne unique pouvant être traitées et polypeptides faits à partir de celles-ci
WO2012006623A1 (fr) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Systèmes pour le traitement du facteur viii et procédés associés
EP2616486B1 (fr) 2010-09-15 2019-01-02 Stichting Sanquin Bloedvoorziening Variants du facteur viii à absorption cellulaire réduite
EA032056B1 (ru) 2010-12-22 2019-04-30 Баксалта Инкорпорейтид Конъюгат терапевтического белка и производного жирной кислоты, способы получения конъюгата терапевтического белка и производного жирной кислоты (варианты)
HUE043921T2 (hu) 2011-02-17 2019-09-30 Univ Pennsylvania Készítmények és módszerek szövetspecifitás módosítására és AAV9-mediált géntranszfer javítására
WO2012170969A2 (fr) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Composés pro-coagulants et leurs procédés d'utilisation
EA029045B1 (ru) 2011-07-08 2018-02-28 Байоджен Хемофилия Инк. Химерные и гибридные полипептиды фактора viii и способы их применения
WO2013016454A1 (fr) 2011-07-25 2013-01-31 Biogen Idec Hemophilia Inc. Dosages pour la surveillance de troubles hémostatiques
AU2012324020A1 (en) 2011-12-30 2013-07-18 Grifols, S.A. Method for purifying Factor VIII
LT2802668T (lt) 2012-01-12 2018-11-26 Bioverativ Therapeutics Inc. Imunogeninio atsako prieš faktorių viii individuose, kuriems skiriama faktoriaus viii terapija, sumažinimas
LT2804623T (lt) 2012-01-12 2019-12-10 Bioverativ Therapeutics Inc Chimeriniai viii faktoriaus polipeptidai ir jų panaudojimas
RS63870B1 (sr) 2012-02-15 2023-01-31 Bioverativ Therapeutics Inc Sastavi faktora viii i postupci za pravljenje i upotrebu istih
WO2013123457A1 (fr) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Protéines de facteur viii de recombinaison
CN104519897A (zh) 2012-06-08 2015-04-15 比奥根艾迪克Ma公司 促凝血化合物
US10202595B2 (en) 2012-06-08 2019-02-12 Bioverativ Therapeutics Inc. Chimeric clotting factors
EP3404105A1 (fr) 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Lignée cellulaire exprimant des polypeptides du facteur viii à chaîne unique et ses utilisations
ES2770501T3 (es) 2012-07-11 2020-07-01 Bioverativ Therapeutics Inc Complejo del factor VIII con XTEN y proteína del factor de Von Willebrand y sus usos
RU2500818C1 (ru) * 2012-07-19 2013-12-10 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК рАР227, КОДИРУЮЩАЯ ПОЛИПЕПТИД РЕКОМБИНАНТНОГО ФАКТОРА VIII СВЕРТЫВАЕМОСТИ КРОВИ ЧЕЛОВЕКА, ЛИНИЯ КЛЕТОК Cricetulus griseus CHO 2H5 - ПРОДУЦЕНТ РЕКОМБИНАНТНОГО ФАКТОРА VIII СВЕРТЫВАЕМОСТИ КРОВИ ЧЕЛОВЕКА И СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА, ОБЛАДАЮЩЕГО АКТИВНОСТЬЮ ФАКТОРА VIII
US10001495B2 (en) 2012-07-25 2018-06-19 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
US10391152B2 (en) 2012-10-18 2019-08-27 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
US20150266944A1 (en) 2012-10-30 2015-09-24 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
HRP20231183T1 (hr) 2013-02-15 2024-01-05 Bioverativ Therapeutics Inc. Optimizirani gen faktora viii
TWI683666B (zh) 2013-03-15 2020-02-01 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
JP6330026B2 (ja) 2013-03-15 2018-05-23 バイオベラティブ セラピューティクス インコーポレイテッド 第ｖｉｉｉ因子ポリペプチド製剤
WO2015012924A2 (fr) 2013-04-29 2015-01-29 The Trustees Of The University Of Pennsylvania Cassettes d'expression préférentielle pour tissus modifiées par un codon, vecteurs les contenant, et utilisation
EP4368194A3 (fr) 2013-06-28 2024-07-31 Bioverativ Therapeutics Inc. Lieur clivable par thrombine ayant xten et ses utilisations
EP3875106A1 (fr) 2013-08-08 2021-09-08 Bioverativ Therapeutics Inc. Purification des molécules fviii chimériques
US20160311885A1 (en) 2013-08-14 2016-10-27 Biogen Ma Inc. Recombinant factor viii proteins
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
WO2015048330A2 (fr) 2013-09-25 2015-04-02 Biogen Idec Ma Inc. Procédés d'inactivation de virus sur colonne
EP3060242A1 (fr) 2013-10-22 2016-08-31 DBV Technologies Procédé pour traiter l'hémophilie en induisant une tolérance de facteurs sanguins
EP3065769A4 (fr) 2013-11-08 2017-05-31 Biogen MA Inc. Composé de fusion procoagulant
WO2015085276A1 (fr) 2013-12-06 2015-06-11 Biogen Idec Ma Inc. Outils pharmacocinétiques de population et leurs utilisations
EP3757116A1 (fr) 2013-12-09 2020-12-30 Sangamo Therapeutics, Inc. Procédés et compositions pour l'ingénierie génomique
SG11201605242YA (en) 2014-01-10 2016-07-28 Biogen Ma Inc Factor viii chimeric proteins and uses thereof
AU2015214245B2 (en) 2014-02-04 2020-09-10 Biogen Ma Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
WO2016012595A1 (fr) * 2014-07-25 2016-01-28 Csl Behring Gmbh Préparations améliorées de facteur viii appropriés pour une utilisation thérapeutique et leurs procédés d'obtention
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
WO2016168728A2 (fr) 2015-04-16 2016-10-20 Emory University Promoteurs et vecteurs recombinés pour l'expression de protéines dans le foie et utilisation associée
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх
EP3411478B1 (fr) 2016-02-01 2022-06-08 Bioverativ Therapeutics Inc. Gènes du facteur viii optimisés
US20200085915A1 (en) 2016-12-02 2020-03-19 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
EP3548066A1 (fr) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc. Méthodes de traitement de l'arthropathie hémophilique à l'aide de facteurs de coagulation chimériques
KR20200035130A (ko) 2017-08-09 2020-04-01 바이오버라티브 테라퓨틱스 인크. 핵산 분자 및 이의 용도
WO2019067766A1 (fr) 2017-09-27 2019-04-04 Sigilon Therapeutics, Inc. Procédés, compositions et éléments implantables comprenant des cellules actives
CA3090136A1 (fr) 2018-02-01 2019-08-08 Bioverativ Therapeutics, Inc. Utilisation de vecteurs lentiviraux exprimant le facteur viii
WO2019195056A1 (fr) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Procédés, compositions et éléments implantables comprenant des cellules souches
TW202014181A (zh) 2018-04-04 2020-04-16 美商希吉隆醫療公司 可植入顆粒及相關方法
TW202015723A (zh) 2018-05-18 2020-05-01 美商百歐維拉提夫治療公司 治療ａ型血友病的方法
MX2021001599A (es) 2018-08-09 2021-07-02 Bioverativ Therapeutics Inc Moleculas de acido nucleico y sus usos para la terapia genica no viral.
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
TW202115127A (zh) 2019-06-19 2021-04-16 美商百歐維拉提夫治療公司 治療血友病及低骨質密度之方法及組成物
JP2023537070A (ja) 2020-08-07 2023-08-30 アミカス セラピューティックス インコーポレイテッド 小胞を標的とするタンパク質及びその使用
JP2024532262A (ja) 2021-08-23 2024-09-05 バイオベラティブ セラピューティクス インコーポレイテッド 最適化第ｖｉｉｉ因子遺伝子
WO2023056331A1 (fr) 2021-09-30 2023-04-06 Bioverativ Therapeutics Inc. Acides nucléiques codant pour des polypeptides du facteur viii à immunogénicité réduite
WO2024081310A1 (fr) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Cellules modifiées et éléments implantables pour le traitement d'une maladie
WO2024081309A1 (fr) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Cellules modifiées et éléments implantables pour le traitement d'une maladie

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR910006424B1 (ko) * 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
JP2525022B2 (ja) * 1986-01-03 1996-08-14 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド ▲ＶＩＩＩ▼：ｃ因子型タンパク質の改良生産方法
EP0251843A1 (fr) * 1986-06-06 1988-01-07 Transgene S.A. Procédé de préparation de facteur VIII à partir de cellules de mammifères
JPH0637425B2 (ja) * 1986-11-11 1994-05-18 株式会社クラレ 高沸点（メタ）アクリル酸エステルの製造方法
FR2619314B1 (fr) * 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
JP2586092B2 (ja) * 1988-04-06 1997-02-26 三菱瓦斯化学株式会社 多官能（メタ）アクリル酸エステルの製造法
ES2112255T3 (es) * 1989-11-17 1998-04-01 Novo Nordisk As Complejos proteicos que tienen actividad del factor viii:c y su produccion.

Also Published As

Publication number Publication date
ES2119769T5 (es) 2006-04-16
EP1293513A3 (fr) 2003-04-02
DK0506757T3 (da) 1999-05-25
AU7039391A (en) 1991-07-18
WO1991009122A1 (fr) 1991-06-27
FI104260B (fi) 1999-12-15
CA2071875C (fr) 2006-08-08
NZ236276A (en) 1993-03-26
FI922745A0 (fi) 1992-06-12
JP2644084B2 (ja) 1997-08-25
NO922325D0 (no) 1992-06-12
HU211504A9 (en) 1995-11-28
EP0506757A1 (fr) 1992-10-07
DE69032600T3 (de) 2006-07-20
NO309041B1 (no) 2000-12-04
AU645539B2 (en) 1994-01-20
DE19975066I2 (de) 2005-07-07
LU90457I2 (fr) 2001-04-13
ES2189897T3 (es) 2003-07-16
DE69032600D1 (de) 1998-10-01
EP0506757B2 (fr) 2005-10-26
NL990035I1 (nl) 1999-12-01
CA2071875A1 (fr) 1991-06-16
DK0506757T4 (da) 2006-02-20
NL990035I2 (nl) 2000-01-03
EP0506757B1 (fr) 1998-08-26
NO922325L (no) 1992-08-11
EP0786474A1 (fr) 1997-07-30
PT96208A (pt) 1991-09-30
SE8904239D0 (sv) 1989-12-15
HK1019449A1 (en) 2000-02-11
IE904510A1 (en) 1991-07-17
ES2119769T3 (es) 1998-10-16
SE465222B (sv) 1991-08-12
JPH05502161A (ja) 1993-04-22
DK0786474T3 (da) 2003-03-03
ATE232213T1 (de) 2003-02-15
DE69034040D1 (de) 2003-03-13
ATE170219T1 (de) 1998-09-15
SE465222C5 (sv) 1998-02-10
EP0786474B1 (fr) 2003-02-05
HK1009290A1 (en) 1999-05-28
SG66753A1 (en) 2001-12-19
SE8904239L (sv) 1991-06-16
BR9007921A (pt) 1992-11-10
EP1293513A2 (fr) 2003-03-19
DE69034040T2 (de) 2003-11-20
PT96208B (pt) 1998-05-29
DE69032600T2 (de) 1999-01-07

Similar Documents

Publication Publication Date Title
FI104260B1 (fi) Biologisesti aktiivista yhdistelmä-DNA-ihmisentekij-VIII-johdannaista koodittava DNA, tämän sisältävä yhdistelmä-DNA-ilmentämisvektori ja isäntäsolu sekä menetelmä biologisesti aktiivisen yhdistelmä-DNA-ihmisentekijä-VIII-johdannaisen valmistamiseksi
SE9100799D0 (sv) Recombinant human factor viii derivatives
DE69434083D1 (de) Expression eines fusionspolypeptides, das ohne leadersequenz aus dem cytoplasma transportiert wird
KR960700340A (ko) 안정한 살균/투과성-증가 단백질 생성물 및 그를 포함하는 제약학적 조성물(stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same)
ATE140029T1 (de) Herstellung von biologischaktivem insulinähnlichem wachstumsfaktor i aus hochexpressions-wirtszellsystemen
NO971621L (no) Keratinocyttvekstfaktoranaloger
ATE253639T1 (de) Verfahren zur herstellung von peptiden
DE68905097D1 (de) Peptid-molekuele, wirksam gegen gram-positive keime.
ES2074087T3 (es) Peptido-señal y secuencias de adn que codifican para el mismo.
von Heijne A sequence correlation between oppositely charged residues in secreted proteins

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: PHARMACIA & UPJOHN AKTIEBOLAG

HC Name/ company changed in application

Owner name: PHARMACIA & UPJOHN AKTIEBOLAG